Corvus Pharmaceuticals, Inc. (CRVS) Deferred Tax Assets, Valuation Allowance USD 2015 - 2023

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Corvus Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from 2015 to 2023.
  • Corvus Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $83 M, a 8.71% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $83 M +$6.65 M +8.71% Dec 31, 2023 10-K 2024-03-19
Q4 2022 $76.3 M +$9.2 M +13.7% Dec 31, 2022 10-K 2024-03-19
Q4 2021 $67.1 M +$11.4 M +20.6% Dec 31, 2021 10-K 2024-03-19
Q4 2020 $55.7 M +$1.46 M +2.69% Dec 31, 2020 10-K 2023-03-28
Q4 2019 $54.2 M +$13 M +31.5% Dec 31, 2019 10-K 2022-03-10
Q4 2018 $41.2 M +$19.4 M +88.4% Dec 31, 2018 10-K 2021-03-25
Q4 2017 $21.9 M +$9.09 M +71.1% Dec 31, 2017 10-K 2020-03-09
Q4 2016 $12.8 M +$6.93 M +118% Dec 31, 2016 10-K 2019-03-07
Q4 2015 $5.87 M Dec 31, 2015 10-K 2018-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.